Table 1.
Demographic information and clinical characteristics.
| Items | IBD(n = 98) | HC(n = 46) | P value |
|---|---|---|---|
| Age (years) | 30.38 ± 8.8 | 27.95 ± 7.5 | 0.112 * |
| Gender (male/female) | 73/25 | 34/12 | 0.941‡ |
| Education (years) | 14.09 ± 2.6 | 14.93 ± 2.2 | 0.061* |
| Disease (n) | |||
| Crohn disease | 64 | – | |
| Ulcerative colitis | 34 | – | |
| Duration of disease (years) | 5.00 ± 4.30 | – | |
| Medication (n) | |||
| Conventional immunosuppressantsa | 38 | – | |
| Biologicsb | 71 | – | |
| Previous surgery (n) | – | ||
| Ileal resection | 13 | ||
| Ostomy | 2 | – | |
| ESR (mm/h) | 19.18 ± 19.23 | – | |
| CRP (mg/L) | 14.39 ± 23.22 | – | |
| IBS-SSS score | 206.15 ± 84.63 | – | |
| GIQLI score | 107.70 ± 23.73 | 128.20 ± 11.70 | < 0.001† |
Values denote mean ± standard deviation or numbers of subjects.
CRP C-reactive protein, ESR erythrocyte sedimentation rate, GIQLI gastrointestinal quality of life index, HC healthy control, IBD inflammatory bowel diseases; IBS-SSS irritable bowel syndrome severity scoring system.
*Independent-samples t-tests.
†Mann–Whitney U-tests.
‡chi-square test.
P < 0.05 was considered significant.
aIncludes corticosteroids, mesalazine, methotrexate, azathioprine, and 6-mercaptopurine.
bInfliximab, adalimumab, ulinumab, vedrizumab.